MC 207110

Drug Profile

MC 207110

Latest Information Update: 04 Oct 2004

Price : $50

At a glance

  • Originator Daiichi Pharmaceutical; Essential Therapeutics [CEASED]
  • Class Antibacterials; Fluoroquinolones
  • Mechanism of Action Membrane protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Pseudomonal infections

Most Recent Events

  • 04 Oct 2004 Discontinued - Preclinical for Pseudomonal infections in Japan (unspecified route)
  • 04 Oct 2004 Discontinued - Preclinical for Pseudomonal infections in USA (unspecified route)
  • 08 Oct 2001 A preclinical study has been added to the Bacterial Infections antimicrobial activity section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top